SEC Tracker
Get the app

Opus Genetics IRD

Opus Genetics announces Q3 2026 results

Opus Genetics (IRD) filed an 8-K with the SEC on Nov 10, 2026, 7:02 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash and cash equivalents of $89.0 million as of September 30, 2026.
  2. R&D expenses increased to $14.5 million for Q3 2026 from $6.4 million in Q3 2025.
  3. FDA approved phentolamine ophthalmic solution 0.75% for presbyopia, triggering a milestone payment.
  4. Cash runway expected to fund operations into 2029.

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Opus Genetics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.